“Today’s listing on Nasdaq is a significant milestone for Sensus Healthcare. With decades of experience in the medical device industry, we launched Sensus with a simple goal – to provide medical professionals and their patients access to non-invasive options to treat non-melanoma skin cancer and keloids,” noted Joseph Sardano, Chief Executive Officer of Sensus Healthcare. “I am extremely proud of the entire Sensus team and wish to express my sincere gratitude for their tireless and continued support.”
About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and marketing with expertise in healthcare, technology and financial / professional services. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.
SOURCE KCSA Worldwide
LHA Investor Relations